Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Thermo Fisher Scientific Inc. pages available for free this week:
- Statement of Comprehensive Income
- Common-Size Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- Analysis of Reportable Segments
- Common Stock Valuation Ratios
- Present Value of Free Cash Flow to Equity (FCFE)
- Current Ratio since 2005
- Price to Sales (P/S) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Thermo Fisher Scientific Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
The overall solvency profile reflects a stable long-term capital structure characterized by consistent leverage ratios, though it is contrasted by a significant contraction in the capacity to service interest expenses.
- Debt-to-Equity and Asset Ratios
- Balance sheet solvency ratios remained relatively stable throughout the period. The debt-to-equity ratio fluctuated between a high of 0.83 and a low of 0.63, with the lowest point occurring in December 2024. Similarly, the debt-to-capital ratio remained narrow, ranging from 0.39 to 0.45, while the debt-to-assets ratio persisted between 0.32 and 0.38. These figures indicate a consistent approach to managing the debt load relative to equity and total assets.
- Financial Leverage
- The financial leverage ratio mirrors the trends seen in the balance sheet ratios. It started at 2.26 in April 2022, declined to a low of 1.96 in December 2024, and subsequently rose back to 2.18 by March 2026. This movement suggests periodic adjustments in the use of debt to finance assets without deviating significantly from the long-term average.
- Interest Coverage
- A significant downward trend is observable in the interest coverage ratio, which dropped from 16.73 in April 2022 to a low of 5.53 in March 2024. This represents a substantial decrease in the ratio of earnings available to cover interest obligations. Following this decline, the ratio stabilized, fluctuating within a narrow range between 5.62 and 6.25 from June 2024 through March 2026, suggesting a new equilibrium in interest servicing capacity.
Debt Ratios
Coverage Ratios
Debt to Equity
| Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Short-term obligations and current maturities of long-term obligations | |||||||||||||||||||||||
| Long-term obligations, excluding current maturities | |||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||
| Total Thermo Fisher Scientific Inc. shareholders’ equity | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Debt to equity1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q1 2026 Calculation
Debt to equity = Total debt ÷ Total Thermo Fisher Scientific Inc. shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The solvency profile is characterized by a fluctuating debt-to-equity ratio that oscillates between 0.63 and 0.83, underpinned by a generally upward trajectory in shareholders' equity. The financial structure demonstrates a pattern of strategic debt management, where periods of deleveraging are followed by capital expansions.
- Debt-to-Equity Ratio Volatility
- A notable decline in the leverage ratio occurred between April 2022 and October 2022, falling from 0.81 to 0.67. Following this, the ratio remained relatively stable, fluctuating within the 0.72 to 0.83 range throughout 2023 and most of 2024. The ratio reached its minimum value of 0.63 on December 31, 2024, before trending upward again to conclude at 0.83 by March 2026.
- Total Debt Movements
- Total debt levels remained largely range-bound between $29 billion and $35 billion from mid-2022 through mid-2024. However, a significant increase in borrowing is observed toward the end of the observed period, with total debt rising from $31.27 billion in December 2024 to $43.16 billion by March 2026. This indicates a substantial expansion of liabilities in the final year of the sequence.
- Shareholders' Equity Expansion
- Shareholders' equity exhibited a consistent growth trend for the majority of the period, rising from $40.95 billion in April 2022 to a peak of $53.40 billion in December 2025. This steady accumulation of equity served as a primary stabilizer for the company's solvency, moderating the impact of debt fluctuations until the sharp increase in borrowing observed in early 2026.
- Overall Solvency Trend
- The convergence of increasing debt and stabilizing equity in the final quarters resulted in a rise in the debt-to-equity ratio from 0.70 in September 2025 to 0.83 in March 2026. This suggests a shift toward a more leveraged capital structure at the end of the analyzed timeframe compared to the more conservative positioning observed in late 2024.
Debt to Capital
| Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Short-term obligations and current maturities of long-term obligations | |||||||||||||||||||||||
| Long-term obligations, excluding current maturities | |||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||
| Total Thermo Fisher Scientific Inc. shareholders’ equity | |||||||||||||||||||||||
| Total capital | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Debt to capital1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q1 2026 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The solvency profile over the analyzed period reflects a disciplined approach to capital structure management, characterized by a stable debt-to-capital ratio despite significant fluctuations in absolute debt and capital levels. While total debt and total capital both exhibit an overall upward trajectory, the proportional relationship between them remains relatively constant, indicating that debt increases have been scaled in alignment with the growth of the total capital base.
- Total Debt Trends
- Absolute debt levels displayed moderate volatility between April 2022 and December 2024, fluctuating between a low of 29,160 million US$ in October 2022 and a peak of 35,608 million US$ in March 2024. A notable reduction to 31,275 million US$ occurred in December 2024. However, a sharp increase is observed in the subsequent periods, with total debt rising to 43,161 million US$ by March 2026, representing a substantial expansion of leverage toward the end of the reporting sequence.
- Total Capital Expansion
- Total capital demonstrates a consistent growth trend, increasing from 74,211 million US$ in April 2022 to 95,095 million US$ by March 2026. This steady expansion of the capital base suggests an increase in the company's overall financial capacity, which has served to mitigate the impact of rising debt levels on the overall solvency ratio.
- Debt to Capital Ratio Analysis
- The debt-to-capital ratio remained within a narrow range of 0.39 to 0.45 throughout the entire period. The ratio reached its lowest point of 0.39 in December 2024, coinciding with a dip in total debt. Despite the aggressive increase in total debt during 2025 and early 2026, the ratio only climbed back to 0.45 by March 2026. This stability indicates that the increase in debt was mirrored by a corresponding increase in total capital, maintaining a balanced capital structure and preventing a disproportionate increase in financial leverage.
Debt to Assets
| Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Short-term obligations and current maturities of long-term obligations | |||||||||||||||||||||||
| Long-term obligations, excluding current maturities | |||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Debt to assets1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q1 2026 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
The solvency profile exhibits a period of relative stability in leverage followed by a notable increase in the final quarters of the analyzed period. The Debt to Assets ratio fluctuated within a narrow corridor between 0.32 and 0.37 from April 2022 through December 2024, suggesting a consistent strategy in balancing debt obligations against the total asset base.
- Debt to Assets Ratio Dynamics
- The ratio reached its lowest points of 0.32 in October 2022 and December 2024, indicating periods of reduced relative leverage. A stable trend persisted through much of 2023 and 2024, with the ratio oscillating around the 0.35 to 0.36 mark. However, a definitive upward shift occurred starting in late 2025, culminating in a peak of 0.38 by March 2026, the highest level recorded in the sequence.
- Total Asset Growth
- A general upward trajectory in the asset base is observed, growing from 92,747 million USD in April 2022 to 113,281 million USD by March 2026. This growth indicates a continuous expansion of the balance sheet, although the pace of growth varied, with a significant jump observed between September 2025 and March 2026.
- Total Debt Accumulation
- Total debt remained relatively range-bound between approximately 29,160 million USD and 35,680 million USD for the majority of the timeline. A significant divergence is noted in the final two reporting periods, where debt rose sharply from 35,680 million USD in June 2025 to 43,161 million USD by March 2026. This accelerated borrowing outpaced asset growth during the same window, leading to the observed increase in the solvency ratio.
Overall, the trend indicates that while the organization maintained a disciplined leverage ratio for several years, the recent surge in total debt has shifted the solvency position toward a higher proportion of debt-funded assets.
Financial Leverage
| Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||
| Total Thermo Fisher Scientific Inc. shareholders’ equity | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Financial leverage1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q1 2026 Calculation
Financial leverage = Total assets ÷ Total Thermo Fisher Scientific Inc. shareholders’ equity
= ÷ =
2 Click competitor name to see calculations.
Total assets demonstrate a general upward trajectory over the analyzed period, increasing from 92,747 million USD in April 2022 to 113,281 million USD by March 2026. This growth is accompanied by a consistent rise in shareholders' equity, which grew from 40,956 million USD to 51,934 million USD, indicating a steady accumulation of net assets.
- Financial Leverage Trajectory
- The financial leverage ratio exhibited a sustained downward trend for the majority of the period. Starting at 2.26 in April 2022, the ratio declined progressively to a minimum of 1.96 by December 2024. This compression suggests a period of deleveraging, where equity growth outpaced asset expansion or total liabilities were reduced.
- Recent Leverage Reversal
- A shift in the leverage pattern occurred after December 2024. The ratio rose from 1.96 to 2.18 by March 2026. This uptick indicates a recent increase in the proportion of debt or other liabilities used to finance assets relative to the equity base.
- Asset and Equity Correlation
- The relationship between total assets and equity remained relatively stable, with the leverage ratio fluctuating within a narrow band between 1.96 and 2.26. The most significant period of stability occurred between April 2023 and September 2023, where the ratio remained nearly flat at approximately 2.14 to 2.15.
The overall financial profile reflects a period of balance sheet expansion. While the company successfully reduced its financial leverage to below 2.00 by the end of 2024, the subsequent increase in the ratio through early 2026 suggests a strategic shift in capital structure or a new phase of asset acquisition funded by external liabilities.
Interest Coverage
| Mar 28, 2026 | Dec 31, 2025 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 31, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Net income attributable to Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Add: Net income attributable to noncontrolling interest | |||||||||||||||||||||||
| Add: Income tax expense | |||||||||||||||||||||||
| Add: Interest expense | |||||||||||||||||||||||
| Earnings before interest and tax (EBIT) | |||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||
| Interest coverage1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Interest Coverage, Competitors2 | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).
1 Q1 2026 Calculation
Interest coverage
= (EBITQ1 2026
+ EBITQ4 2025
+ EBITQ3 2025
+ EBITQ2 2025)
÷ (Interest expenseQ1 2026
+ Interest expenseQ4 2025
+ Interest expenseQ3 2025
+ Interest expenseQ2 2025)
= ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The interest coverage profile exhibits a distinct two-phase trajectory: a period of sharp contraction followed by a phase of sustained stability. Between April 2022 and March 2024, the coverage ratio declined precipitously from 16.73 to 5.53, representing a significant reduction in the operating margin available to service interest obligations. Following this contraction, the ratio entered a period of equilibrium, fluctuating narrowly between 5.53 and 6.25 through March 2026.
- Earnings Before Interest and Tax (EBIT) Trends
- Operating earnings demonstrated notable volatility, beginning at 2,657 million in April 2022 and reaching a trough of 1,638 million in April 2023. Subsequently, EBIT showed a recovery trend, generally oscillating between 1,900 million and 2,500 million throughout the 2024 and 2025 periods, providing a stabilized base for debt servicing.
- Interest Expense Trajectory
- A substantial increase in borrowing costs is observed, with interest expenses rising from 136 million in April 2022 to a peak of 390 million in December 2023. This nearly threefold increase acted as the primary catalyst for the compression of the interest coverage ratio. From January 2024 onward, interest expenses leveled off, remaining within a range of 303 million to 404 million.
- Solvency and Coverage Interpretation
- The convergence of stabilized operating earnings and leveled interest expenses resulted in a consistent interest coverage ratio starting in the first quarter of 2024. Although the ratio remains substantially lower than the levels seen in early 2022, the consistent maintenance of a ratio above 5.5 suggests a stable capacity to meet interest obligations from current operating profits.